145 related articles for article (PubMed ID: 28870789)
1. Panitumumab in Combination With Preoperative Radiation Therapy in Patients With Locally Advanced RAS Wild-type Rectal Cancer: Results of the Multicenter Explorative Single-Arm Phase 2 Study NEORIT.
Merx K; Martens UM; Kripp M; Hoehler T; Geissler M; Gaiser T; Mai S; Kienle P; Belle S; Plöger C; Hieber U; Wenz F; Post S; Hofheinz RD
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):867-875. PubMed ID: 28870789
[TBL] [Abstract][Full Text] [Related]
2. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
Kim SY; Shim EK; Yeo HY; Baek JY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Jung KH; Chang HJ
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):201-7. PubMed ID: 22672749
[TBL] [Abstract][Full Text] [Related]
3. Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03).
Pinto C; Di Bisceglie M; Di Fabio F; Bochicchio A; Latiano T; Cordio S; Rosati G; Aschele C; Marino A; Bergamo F; Bustreo S; Frassineti L; Ciardiello F; Damato A; Giaquinta S; Baldari D; Boni L
Oncologist; 2018 Aug; 23(8):912-918. PubMed ID: 29523646
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.
Helbling D; Bodoky G; Gautschi O; Sun H; Bosman F; Gloor B; Burkhard R; Winterhalder R; Madlung A; Rauch D; Saletti P; Widmer L; Borner M; Baertschi D; Yan P; Benhattar J; Leibundgut EO; Bougel S; Koeberle D
Ann Oncol; 2013 Mar; 24(3):718-25. PubMed ID: 23139259
[TBL] [Abstract][Full Text] [Related]
5. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
Kim SY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Lee KS; Yun T; Jeong SY; Choi HS; Lim SB; Chang HJ; Jung KH
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):677-83. PubMed ID: 20888703
[TBL] [Abstract][Full Text] [Related]
6. Preoperative short-course concurrent chemoradiation therapy followed by delayed surgery for locally advanced rectal cancer: a phase 2 multicenter study (KROG 10-01).
Yeo SG; Oh JH; Kim DY; Baek JY; Kim SY; Park JW; Kim MJ; Chang HJ; Kim TH; Lee JH; Jang HS; Kim JG; Lee MA; Nam TK
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):34-9. PubMed ID: 23265569
[TBL] [Abstract][Full Text] [Related]
7. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
[TBL] [Abstract][Full Text] [Related]
8. Acute Toxicity and Tumor Response in Locally Advanced Rectal Cancer After Preoperative Chemoradiation Therapy With Shortening of the Overall Treatment Time Using Intensity-Modulated Radiation Therapy With Simultaneous Integrated Boost: A Phase 2 Trial.
But-Hadzic J; Anderluh F; Brecelj E; Edhemovic I; Secerov-Ermenc A; Hudej R; Jeromen A; Kozelj M; Krebs B; Oblak I; Omejc M; Vogrin A; Velenik V
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1003-1010. PubMed ID: 27727065
[TBL] [Abstract][Full Text] [Related]
9. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
Erben P; Ströbel P; Horisberger K; Popa J; Bohn B; Hanfstein B; Kähler G; Kienle P; Post S; Wenz F; Hochhaus A; Hofheinz RD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1032-8. PubMed ID: 20947270
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).
von Moos R; Koeberle D; Schacher S; Hayoz S; Winterhalder RC; Roth A; Bodoky G; Samaras P; Berger MD; Rauch D; Saletti P; Plasswilm L; Zwahlen D; Meier UR; Yan P; Izzo P; Klingbiel D; Bärtschi D; Zaugg K;
Eur J Cancer; 2018 Jan; 89():82-89. PubMed ID: 29241084
[TBL] [Abstract][Full Text] [Related]
11. Acute small-bowel toxicity during neoadjuvant combined radiochemotherapy in locally advanced rectal cancer: determination of optimal dose-volume cut-off value predicting grade 2-3 diarrhoea.
Reis T; Khazzaka E; Welzel G; Wenz F; Hofheinz RD; Mai S
Radiat Oncol; 2015 Jan; 10():30. PubMed ID: 25636703
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer.
Wang L; Li ZY; Li ZW; Li YH; Sun YS; Ji JF; Gu J; Cai Y
Dis Colon Rectum; 2015 Feb; 58(2):186-92. PubMed ID: 25585076
[TBL] [Abstract][Full Text] [Related]
13. EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.
Hu-Lieskovan S; Vallbohmer D; Zhang W; Yang D; Pohl A; Labonte MJ; Grimminger PP; Hölscher AH; Semrau R; Arnold D; Dellas K; Debucquoy A; Haustermans K; Machiels JP; Sempoux C; Rödel C; Bracko M; Velenik V; Lenz HJ
Clin Cancer Res; 2011 Aug; 17(15):5161-9. PubMed ID: 21673069
[TBL] [Abstract][Full Text] [Related]
14. Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study.
Fokas E; Conradi L; Weiss C; Sprenger T; Middel P; Rau T; Dellas K; Kitz J; Rödel F; Sauer R; Rüschoff J; Beissbarth T; Arnold D; Ghadimi BM; Rödel C; Liersch T
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):992-9. PubMed ID: 24210078
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer.
Grimminger PP; Danenberg P; Dellas K; Arnold D; Rödel C; Machiels JP; Haustermans K; Debucquoy A; Velenik V; Sempoux C; Bracko M; Hölscher AH; Semrau R; Yang D; Danenberg K; Lenz HJ; Vallböhmer D
Clin Cancer Res; 2011 May; 17(10):3469-77. PubMed ID: 21558395
[TBL] [Abstract][Full Text] [Related]
17. Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer.
Jin T; Zhu Y; Luo JL; Zhou N; Li DC; Ju HX; Fan YT; Liu Y; Zhu YP; Feng HY; Liu LY
Int J Colorectal Dis; 2015 Mar; 30(3):337-45. PubMed ID: 25564344
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer.
Velenik V; Ocvirk J; Oblak I; Anderluh F
Eur J Surg Oncol; 2010 Mar; 36(3):244-50. PubMed ID: 20042310
[TBL] [Abstract][Full Text] [Related]
19. Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial.
Ballonoff A; Kavanagh B; McCarter M; Kane M; Pearlman N; Nash R; Shah RJ; Raben D; Schefter TE
Am J Clin Oncol; 2008 Jun; 31(3):264-70. PubMed ID: 18525306
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of preoperative pelvic radiation therapy and concomitant boost irradiation in locally advanced rectal cancer patients: a multi-institutional phase II study (KROG 04-01).
Lee JH; Kim DY; Nam TK; Yoon SC; Lee DS; Park JW; Oh JH; Chang HJ; Yoon MS; Jeong JU; Jang HS
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):955-61. PubMed ID: 22537540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
